Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms
| Autor: | Otto Benkert, Hermann Wetzel, A. Hillert, Gerd Gründer |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Agonist
medicine.medical_specialty Psychosis medicine.drug_class Dopamine Agents Gastroenterology Receptors Dopamine chemistry.chemical_compound Roxindole Internal medicine mental disorders Schizophrenic Psychology medicine Humans Prospective Studies Scale for the Assessment of Negative Symptoms Psychiatric Status Rating Scales Schizophrenia Paranoid Dose-Response Relationship Drug business.industry medicine.disease Hospitalization Psychiatry and Mental health Treatment Outcome Endocrinology chemistry Schizophrenia Dopamine receptor Autoreceptor business |
| Zdroj: | American Journal of Psychiatry. 151:1499-1502 |
| ISSN: | 1535-7228 0002-953X |
| DOI: | 10.1176/ajp.151.10.1499 |
| Popis: | Twenty schizophrenic inpatients with either predominantly positive or predominantly negative symptoms were treated with the dopamine autoreceptor agonist roxindole in prospective open clinical trials. There was no antipsychotic effect in the subgroup with positive symptoms, whereas the subgroup with negative symptoms, especially those with the residual type of schizophrenia, showed a moderate but significant 20% reduction in total scores on the Scale for the Assessment of Negative Symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|